Paul Fehlner Net Worth

The estimated Net Worth of Paul Fehlner is at least $269 mil dollars as of 10 February 2023. Paul Fehlner owns over 5,221 units of Axcella Health Inc stock worth over $266,011 and over the last 5 years he sold AXLA stock worth over $3,446. In addition, he makes $0 as Senior Vice President y Chief Intellectual Property Officer at Axcella Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Fehlner AXLA stock SEC Form 4 insiders trading

Paul has made over 2 trades of the Axcella Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 5,221 units of AXLA stock worth $3,446 on 10 February 2023.

The largest trade he's ever made was buying 10,471 units of Axcella Health Inc stock on 16 March 2022 worth over $20,000. On average, Paul trades about 2,242 units every 47 days since 2019. As of 10 February 2023 he still owns at least 58,081 units of Axcella Health Inc stock.

You can see the complete history of Paul Fehlner stock trades at the bottom of the page.

Paul Fehlner biography

Dr. Paul Fehlner serves as Senior Vice President, Chief Intellectual Property Officer of the Company. In addition, Dr. Fehlner has served as a Principal at Life Sciences Innovation LLC, an intellectual property and legal consulting firm, since December 2017. From November 2008 through November 2017, Dr. Fehlner served as Global Head of Intellectual Property at Novartis Pharma AG in Basel, Switzerland.

How old is Paul Fehlner?

Paul Fehlner is 56, he's been the Senior Vice President y Chief Intellectual Property Officer of Axcella Health Inc since 2018. There are 7 older and 9 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.

What's Paul Fehlner's mailing address?

Paul's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., P.O. BOX 1270, LITTLETON, MA, 01460.

Insiders trading at Axcella Health Inc

Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... y Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.

What does Axcella Health Inc do?

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.

Complete history of Paul Fehlner stock trades at Axcella Health Inc

Axcella Health Inc executives and stock owners

Axcella Health Inc executives and other stock owners filed with the SEC include:

• Shreeram Aradhye,
  Executive Vice President, Chief Development Officer
• Manu Chakravarthy,
  Senior Vice President, Chief Medical Officer
• William Hinshaw,
  President, Chief Executive Officer, Director
• David Epstein,
  Chairman of the Board
• William R. Hinshaw Jr.,
  Pres, CEO & Director
• Laurent Chardonnet,
  Consultant
• William Baird,
  Independent Director
• Catherine Sohn,
  Independent Director
• Gary Pisano,
  Independent Director
• Gregory Behar,
  Independent Director
• Cristina Rondinone,
  Independent Director
• Stephen Hoge,
  Independent Director
• Stephen Mitchener,
  Senior Vice President, Chief Business Officer
• Paul Fehlner,
  Senior Vice President, Chief Intellectual Property Officer
• Heidy King-Jones,
  Senior Vice President of Legal, General Counsel
• Tony Tramontin,
  Senior Vice President of Research and Development , Chief Scientific Officer
• Laurent Chardonnet,
  Chief Financial Officer, Senior Vice President
• Karim Azer Ph.D.,
  VP of Systems Biology & Discovery
• Dr. Margaret Koziel M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Alison D. Schecter M.D.,
  Pres of R&D
• Dr. Larry Bell,
  Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
• Virginia R. Dean,
  Sr. VP & Chief People Officer
• Dr. Paul Fehlner J.D., Ph.D.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Jason Fredette,
  VP of Investor Relations & Corp. Communications
• Health Science Us Holdings,...,
  
• Michael Rosenblatt,
  Director
• David A Berry,
  Director
• Ventures Fund Iv General Pa...,
  
• Paul J Sekhri,
  Director
• Ventures Fund Iv General Pa...,
  
• Des Produits Nestle S.A.Nes...,
  
• Alison D. Schecter,
  President - Research & Dev.
• Virginia R Dean,
  SVP, Chief People Officer
• Margaret Koziel,
  Chief Medical Officer
• Ventures Fund Iv General Pa...,
  
• Robert Crane,
  Chief Financial Officer
• Torben Straight Nissen,
  Director
• Robert L. Rosiello,
  Director